scholarly article | Q13442814 |
P356 | DOI | 10.1002/IJC.11338 |
P698 | PubMed publication ID | 12918074 |
P50 | author | Olga Haus | Q11797861 |
Jan Lubiński | Q11718282 | ||
Izabella Rzepka-Górska | Q114456255 | ||
Helena Zientek | Q117235135 | ||
Stanisław Góźdź | Q18590952 | ||
Jerzy Roman Kowalczyk | Q21328387 | ||
Steven A. Narod | Q50384888 | ||
Anna Jakubowska | Q58323317 | ||
Marek Bebenek | Q114333817 | ||
Malgorzata Stawicka-Nielacna | Q114456213 | ||
Marek Szwiec | Q114456232 | ||
Hanna Janiszewska | Q114456244 | ||
Dariusz Godlewski | Q114456246 | ||
Małgorzata Foszczyńska-Kłoda | Q114456248 | ||
Izabela Brozek | Q114456249 | ||
Beata Kozak-Klonowska | Q114456250 | ||
Roman Miturski | Q114456251 | ||
Stanisław Niepsuj | Q114456252 | ||
Bernard Waśko | Q114456253 | ||
Andrzej Rozmiarek | Q114456254 | ||
Tomasz Byrski | Q58345332 | ||
Janusz Menkiszak | Q58898660 | ||
Ewa Grzybowska | Q62589470 | ||
Andrzej Mackiewicz | Q89457664 | ||
Jacek Gronwald | Q91084015 | ||
Tomasz Huzarski | Q97187823 | ||
Bohdan Górski | Q98618546 | ||
P2093 | author name string | Krzysztof Urbański | |
Katarzyna Lamperska | |||
Magdalena Perkowska | |||
Jan Koc | |||
Kazimierz Drosik | |||
Anna Pluzańska | |||
Elwira Strózyk | |||
P2860 | cites work | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer | Q24540270 |
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan | Q24611839 | ||
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history | Q33869223 | ||
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary | Q33900686 | ||
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer | Q34113283 | ||
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation | Q34129784 | ||
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations | Q34129787 | ||
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer | Q34145544 | ||
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | Q34162534 | ||
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations | Q40718941 | ||
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics | Q44060672 | ||
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients | Q44969666 | ||
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group | Q47701078 | ||
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation | Q48070015 | ||
Genetic epidemiology of BRCA1 mutations in Norway. | Q53145195 | ||
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. | Q55034444 | ||
Contribution of BRCA1 mutations to ovarian cancer | Q73215230 | ||
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland | Q73734735 | ||
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer | Q73782102 | ||
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study | Q73936350 | ||
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing | Q74525381 | ||
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online | Q78125794 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Poland | Q36 |
ovarian cancer | Q172341 | ||
P304 | page(s) | 942-945 | |
P577 | publication date | 2003-10-01 | |
P1433 | published in | International Journal of Cancer | Q332492 |
P1476 | title | Hereditary ovarian cancer in Poland | |
P478 | volume | 106 |
Q89999716 | A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy |
Q34548008 | A high proportion of founder BRCA1 mutations in Polish breast cancer families |
Q33722598 | BRCA1 4153delA founder mutation in Russian ovarian cancer patients |
Q53506544 | BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. |
Q44221699 | BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases |
Q34185187 | BRCA1 founder mutations compared to ovarian cancer in Belarus |
Q37327095 | BRCA1 testing |
Q37011738 | Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations |
Q36930042 | Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status |
Q36446316 | Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients |
Q91639244 | Current Genetic Service Delivery Models for the Provision of Genetic Testing in Europe: A Systematic Review of the Literature |
Q36903256 | Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases |
Q40821559 | Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? |
Q38609944 | Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation |
Q37720438 | Epidemiology of ovarian cancer: a review |
Q36117690 | Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control |
Q57579994 | Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia |
Q50320232 | Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. |
Q92354777 | Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome |
Q35060014 | Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy |
Q34059765 | Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia |
Q93032475 | Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study |
Q33458308 | Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor |
Q35944416 | Hereditary breast-ovarian cancer syndrome in Russia. |
Q37147699 | High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients |
Q81587439 | High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland |
Q36474986 | High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing |
Q43522641 | High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia |
Q35828679 | Improved survival in BRCA2 carriers with ovarian cancer |
Q37123377 | Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing |
Q84817507 | Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers |
Q38221583 | Multiple primary cancers as a guide to heritability |
Q35546258 | Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing |
Q34705352 | On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations |
Q79772653 | PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations |
Q39958494 | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
Q37697025 | Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry |
Q50849096 | Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine. |
Q33584095 | The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome |
Q26741851 | The biological effects and clinical implications of BRCA mutations: where do we go from here? |
Q37453854 | The contribution of BRCA1 and BRCA2 to ovarian cancer |
Q38809495 | The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania |
Search more.